AI Article Synopsis
- - SARS-CoV-2, known for causing COVID-19, has been a major health concern since the pandemic declaration in March 2020, with connections to various organ systems including the skin.
- - Skin manifestations of COVID-19 are categorized into types like vesicular, chilblains-like ("COVID toes"), maculopapular, and urticarial, highlighting the diversity of dermatological symptoms.
- - The review focuses on the pathophysiology behind these skin manifestations, their prevalence, clinical features, and management, using data from multiple studies and case reports until June 2022.
Article Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been a rising concern since its declaration as a pandemic by the World Health Organization on 11 March 2020. Recently, its association with multiple underlying organs has been identified that includes cardiac, renal, gastrointestinal, nervous systems, and cutaneous manifestations. Cutaneous COVID-19 findings have been supposedly classified into the following categories: vesicular (varicella-like), papulo-vesiculsar, chilblains-like ("COVID toes") maculopapular, and urticarial morphologies. In this review, we aim to focus on the proposed pathophysiology behind the various dermatological manifestations associated with COVID-19 and their associated management. We also included prevalence and clinical features of the different COVID-19-related skin lesions in our review. A comprehensive narrative review of the literature was performed in PubMed databases. Data from case reports, observational studies, case series, and reviews till June 2022 were all screened and included in the review.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500986 | PMC |
| http://dx.doi.org/10.3390/v14091972 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous manifestations in D-2-hydroxyglutaric aciduria type 2 and response to enasidenib therapy.
JAAD Case Rep
February 2025
Metabolic Disorders Division, Children's Hospital of Orange County, Orange, California.
Scleredema: An Unusual Cutaneous Manifestation of Coronavirus Infection.
Adv Skin Wound Care
January 2025
In the Department of Dermatology, Employees' State Insurance Corporation-Post Graduate Institute of Medical Sciences and Research, in Basaidarapur, New Delhi, India. Priyanka Hemrajani, MD, is Assistant Professor; Mona Sharma, MD, and Piyush Gupta, MD, are Senior Residents; Tapan Kumar Dhali, MD, is Professor; and Paschal D'souza, MD, is Professor and Head of Department. The authors have disclosed no financial relationships related to this article. Submitted April 8, 2023; accepted in revised form April 2, 2024.
The global pandemic caused by COVID-19 led to numerous novel cases of autoimmune and rheumatologic disorders that developed postinfection. Along these lines, these authors report an unusual case of scleredema following SARS-CoV-2 infection in an individual who lacked any known risk factors. Given the emergence of newer mutant strains of COVID-19 and steadily rising numbers of people receiving COVID-19 vaccinations, physicians should remain alert for as yet unrecognized manifestations of the disease.
View Article and Find Full Text PDFA unique case of extranodal marginal zone lymphoma with synchronous pulmonary and dermatologic manifestations.
Respir Med Case Rep
December 2024
Division of Pulmonary and Critical Care, University of Rochester, Rochester, NY, USA.
An 89-year-old male with a medical history of non-ischemic cardiomyopathy was initially admitted with acute hypoxic respiratory failure attributed to heart failure exacerbation. Aside from progressive dyspnea, a non-pruritic, non-painful rash and constitutional symptoms were reported. Initial work-up was remarkable for normocytic anemia, lymphopenia, mild hypercalcemia, and elevated inflammatory markers.
View Article and Find Full Text PDFMast cell activation induced by tamoxifen citrate via MRGPRX2 plays a potential adverse role in breast cancer treatment.
Biochem Pharmacol
January 2025
School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, PR China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, PR China. Electronic address:
Breast cancer is the most common malignant tumor endangering women's life and health. Tamoxifen citrate (TAM) is the first-line drug of adjuvant endocrine therapy for estrogen receptor-positive (ER) breast cancer patients. Some sporadic cases have described rare adverse reactions of TAM with potentially life-threatening dermatological manifestations, which were associated with skin allergy.
View Article and Find Full Text PDFSecondary cryofibrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study.
Clin Rheumatol
January 2025
Rheumatology Unit, Scleroderma Unit, University Hospital of Modena, Via del Pozzo, 71-41125, Modena, Italy.
The aims of this study were to investigate the prevalence of cryofibrinogenemia in a cohort of patients with systemic sclerosis (SSc) regardless of clinical manifestations, who were admitted to our hospital and determine the associations among CF positivity, disease features and ongoing therapies. This was a monocentric and retrospective study. The inclusion criteria were a diagnosis of SSc (according to the ACR/EULAR 2013 classification criteria), regular administration of i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!